How Gilead Is Driving Global Health Equity And Innovation [Forbes]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Forbes
Lenacapavir, Gilead Sciences' (NASDAQ: GILD) innovative therapy for HIV pre-exposure prophylaxis (PrEP), is not only a breakthrough in clinical efficacy but also a model for advancing equitable healthcare access. “With clinical trials showing a 100% prevention rate among cisgender women in the PURPOSE 1 trial and a 96% reduction in infection rates among cisgender men and gender-diverse people in the PURPOSE 2 trial, the therapy offers hope for individuals and overburdened healthcare systems worldwide,” says Daniel O'Day, Chairman and CEO of Gilead. According to Mitchell Warren, Executive Director of AVAC, an international non-profit organization working to accelerate effective HIV prevention options in high-burden countries and communities, “the recent results of injectable lenacapavir for PrEP are among the most important results we've seen to date of any HIV prevention option. Adding this additional HIV prevention options means more people may find an option that is right for th
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Moderna (MRNA) Q4 Earnings Report Preview: What To Look For [Yahoo! Finance]Yahoo! Finance
- IDEAYA announces expanded collaboration with Gilead Sciences [Seeking Alpha]Seeking Alpha
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at DZ Bank AG from a "hold" rating to a "buy" rating. They now have a $108.00 price target on the stock.MarketBeat
- February 2025's Undervalued Stock Selections For Potential Investment Opportunities [Yahoo! Finance]Yahoo! Finance
- Why Gilead Sciences (GILD) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/11/25 - Beat
GILD
Sec Filings
- 2/13/25 - Form 4
- 2/13/25 - Form 13F-HR
- 2/12/25 - Form 144
- GILD's page on the SEC website